Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Regulus Therapeutics (RGLS)

Regulus Therapeutics (RGLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Regulus: Q1 Earnings Snapshot AP - Thu May 8, 2025

Regulus: Q1 Earnings Snapshot

RGLS : 8.16 (+0.25%)
Regulus: Q4 Earnings Snapshot AP - Thu Mar 13, 2025

Regulus: Q4 Earnings Snapshot

RGLS : 8.16 (+0.25%)
Regulus: Q3 Earnings Snapshot AP - Thu Nov 7, 2024

Regulus: Q3 Earnings Snapshot

RGLS : 8.16 (+0.25%)
Regulus: Q2 Earnings Snapshot AP - Thu Aug 8, 2024

Regulus: Q2 Earnings Snapshot

RGLS : 8.16 (+0.25%)
Regulus: Q1 Earnings Snapshot AP - Thu May 9, 2024

Regulus: Q1 Earnings Snapshot

RGLS : 8.16 (+0.25%)
Regulus: Q4 Earnings Snapshot AP - Thu Mar 21, 2024

Regulus: Q4 Earnings Snapshot

RGLS : 8.16 (+0.25%)
Regulus: Q3 Earnings Snapshot AP - Thu Nov 9, 2023

Regulus: Q3 Earnings Snapshot

RGLS : 8.16 (+0.25%)
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire - Thu Oct 19, 2023

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

RGLS : 8.16 (+0.25%)
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire - Wed Sep 20, 2023

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

RGLS : 8.16 (+0.25%)
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire - Wed Sep 13, 2023

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

RGLS : 8.16 (+0.25%)

Barchart Exclusives

1 Trade to Make as the Pro Farmer Crop Tour Wraps Up Barchart - 5 minutes ago
December soybean meal futures present a buying opportunity on more price strength. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.